Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00109502" target="_blank" >RIV/00216224:14110/19:00109502 - isvavai.cz</a>
Výsledek na webu
<a href="http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract" target="_blank" >http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2018.213157" target="_blank" >10.3324/haematol.2018.213157</a>

Jazyk výsledku
angličtina
Název v původním jazyce
Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.
Popis výsledku v původním jazyce
Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
Název v anglickém jazyce
Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.
Popis výsledku anglicky
Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.

Projekt
<a href="/cs/project/LM2015090" target="_blank" >LM2015090: Český národní uzel Evropské sítě infrastruktur klinického výzkumu</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)